BT
The startup develops a drug administration technology that utilizes intrathecal infusion to deliver riluzole directly to patients with amyotrophic lateral sclerosis. This method provides a targeted treatment for central nervous system diseases, minimizing systemic side effects and enhancing the efficacy of life-altering medications.
Updated 3 months ago
Funding
$400K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops a drug administration technology that utilizes intrathecal infusion to deliver riluzole directly to patients with amyotrophic lateral sclerosis. This method provides a targeted treatment for central nervous system diseases, minimizing systemic side effects and enhancing the efficacy of life-altering medications.